Free Trial

Kenvue CEO Mongon leaves the consumer health company as it continues its strategic review

This is a display of Johnson and Johnson's Band-Aids in a Costco Warehouse in Pittsburgh, Jan. 26, 2023. (AP Photo/Gene J. Puskar, file)

Key Points

  • Thibaut Mongon is stepping down as CEO of Kenvue as the company continues its strategic review, with board member Kirk Perry named interim CEO effective immediately.
  • Spun off from Johnson & Johnson's consumer health division in 2021, Kenvue is exploring a broad range of potential alternatives to simplify its portfolio and operations.
  • For the fiscal second quarter, Kenvue expects adjusted earnings of $0.28–$0.29 per share, matching the FactSet consensus of $0.28.
  • Shares of Kenvue rose more than 4% in pre-market trading following the leadership change and strategic update.
  • MarketBeat previews top five stocks to own in August.
  • Limited Time Offer: Unlock powerful research tools, advanced financial data, and expert insights to help you invest with confidence. Save 50% when you upgrade to MarketBeat All Access during the month of July. Claim your discount here.

Kenvue says that Thibaut Mongon is leaving as CEO as the maker of Listerine and Band-Aid brands continues with a strategic review of the company.

Kenvue used to be a part of Johnson & Johnson. J&J announced in late 2021 that it was splitting its consumer health division from the pharmaceutical and medical device divisions in a bid to make each more nimble.

Kenvue said Monday that board member Kirk Perry will serve as interim CEO, effective immediately. Perry has served as a director since December and most recently served as CEO of Circana, a provider of market research. He spent more than 20 years at Procter & Gamble in various roles.

Kenvue also said that it is continuing to work with its strategic review committee to explore options for the company.

“The Board’s strategic review is underway, and we are considering a broad range of potential alternatives, including ways to simplify the Company’s portfolio and how it operates," Chair Larry Merlo said in a statement.

Kenvue provided some preliminary results for its fiscal second quarter. The company anticipates adjusted earnings in a range of 28 cents to 29 cents per share. Analysts polled by FactSet expect earnings of 28 cents per share.

Kenvue will report its full quarterly results on Aug. 7 and said that it will revise its full-year outlook on that date.

Shares rose more than 4% before the market open.

Where Should You Invest $1,000 Right Now?

Before you make your next trade, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis.

Our team has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and none of the big name stocks were on the list.

They believe these five stocks are the five best companies for investors to buy now...

See The Five Stocks Here

7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Pelosi Makes Big Bet on Broadcom—Here’s Why It Matters
This Strategy Beat the S&P—And Most Investors Ignore It
NVDA Greenlight: China Sales Spark 50% Rally Potential

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines